Table 2.
Baseline characteristics - cohort 2 (Collaborative Cohort Study, Heidelberg).
| Characteristics | All recipients | KLRC2 wt/wt | KLRC2 wt/del | NKG2Cdel/del | P value |
|---|---|---|---|---|---|
| n=1,860 | n=1,247 | n=530 | n=83 | ||
| Female recipient sex, n (%) | 725 (39) | 481 (39) | 215 (41) | 29 (35) | 0.54 |
| Recipient age, mean ± SD (years) | 46.6 ± 13.8 | 46.7 ± 13.8 | 46.2 ± 14.0 | 47.5 ± 12.7 | 0.62 |
| Geographic origin, n (%) | 0.29 | ||||
| Europe | 1,646 (88) | 1,107 (89) | 470 (89) | 69 (83) | |
| Northern America | 214 (12) | 140 (11) | 60 (11) | 14 (7) | |
| First renal allograft, n (%) | 1,620 (87) | 1,077 (86) | 469 (88) | 74 (89) | 0.40 |
| Underlying renal disease, n (%) | 0.86 | ||||
| Glomerulonephritis | 593 (32) | 404 (32) | 165 (31) | 24 (29) | |
| Polycystic kidneys | 236 (13) | 153 (12) | 72 (14) | 11 (13) | |
| Diabetes mellitus | 171 (9) | 120 (10) | 42 (8) | 9 (11) | |
| Other | 860 (46) | 570 (46) | 251 (47) | 39 (47) | |
| Donor age, mean ± SD (years) | 40.3 ± 16.6 | 40.1 ± 16.7 | 40.7 ± 16.3 | 41.3 ± 16.0 | 0.65 |
| Cold ischemia time, mean ± SD (hours) | 20.5 ± 8.3 | 20.1 ± 8.1 | 21.2 ± 8.1 | 21.8 ± 11.5 | 0.021 |
| HLA A+B+DR mismatches, n (%) | 0.087 | ||||
| 0 – 1 | 217 (12) | 134 (11) | 76 (14) | 7 (8) | |
| 2 – 4 | 1,384 (74) | 948 (76) | 375 (71) | 61 (73) | |
| 5 – 6 | 259 (14) | 165 (13) | 79 (15) | 15 (18) | |
| Panel-reactive antibodies >0% a , n (%) | 412 (24) | 283 (24) | 115 (23) | 14 (19) | 0.56 |
| Initial immunosuppression, n (%) | |||||
| Calcineurin inhibitor, n (%) | 0.82 | ||||
| Cyclosporine A | 1,509 (81) | 1,008 (81) | 430 (81) | 71 (86) | |
| Tacrolimus | 261 (14) | 177 (14) | 76 (14) | 8 (10) | |
| None | 90 (5) | 62 (5) | 24 (5) | 4 (5) | |
| Antimetabolite agent, n (%) | 0.016 | ||||
| Azathioprine | 903 (47) | 579 (46) | 286 (54) | 43 (52) | |
| Mycophenolic acid | 648 (33) | 404 (32) | 144 (27) | 30 (36) | |
| None | 389 (20) | 264 (21) | 100 (19) | 10 (12) | |
| Induction therapy, n (%) | 0.98 | ||||
| IL-2R antibody | 139 (8) | 90 (8) | 42 (8) | 7 (9) | |
| Depleting anti-lymphocyte agent | 412 (23) | 277 (24) | 117 (23) | 18 (24) | |
| None | 1,208 (69) | 811 (69) | 347 (69) | 50 (67) |
SD, standard deviation; HLA, human leukocyte antigen; IL-2R, interleukin 2 receptor.
a
For 131 (7%) recipients, levels of panel-reactive antibodies were not available.